Boston Scientific's ACURATE neo2 Aortic Valve System Fails To Meet Non-Inferiority In Key Trial, Showing 16.16% Composite Rate Of Mortality, Stroke, Or Rehospitalization At One Year Versus 9.53% For Control Valve; Data Presented At TCT 2024
Portfolio Pulse from Benzinga Newsdesk
Boston Scientific's ACURATE neo2 Aortic Valve System did not meet non-inferiority in a key trial, showing a higher composite rate of mortality, stroke, or rehospitalization compared to the control valve. The data was presented at TCT 2024.
October 30, 2024 | 3:43 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Boston Scientific's ACURATE neo2 Aortic Valve System failed to meet non-inferiority in a key trial, showing a 16.16% composite rate of adverse outcomes compared to 9.53% for the control valve.
The failure to meet non-inferiority in a key trial for the ACURATE neo2 Aortic Valve System suggests potential challenges in market acceptance and competitiveness, likely leading to negative investor sentiment and a short-term decline in BSX stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100